INTRODUCTION
============

Prediabetes is defined as a state of intermediate hyperglyce mia using two specific parameters, impaired fasting glucose defined as fasting plasma glucose of 110 mg/dL to 125 mg/dL and impaired glucose tolerance (IGT) defined as 2-h plasma glucose of 140-200 mg/dL after ingestion of 75 g of oral glucose load or a combination of the two based on a 2-h oral glucose tolerance test (OGTT).[@B1] IGT and impaired fasting glycemia have been found to be markers of increased risk for the development of type 2 diabetes mellitus (DM).[@B2] Previous studies have shown that prediabetes is an independent risk factor for cardiovascular disease[@B3] and that prediabetes is associated with an increased risk of coronary and cardiovascular death.[@B4]

Abnormal hemoglobin A1c (HbA1c) level has been found to hold prognostic significance in non-diabetic patients undergoing percutaneous coronary intervention (PCI).[@B5][@B6] However, data regarding the impact of prediabetes on long-term clinical outcomes in patients undergoing PCI with drug-eluting stents (DESs) are limited. In the 1st generation DES era, the incidence of major adverse cardiac events (MACE) and specific cardiovascular events during a 3-year follow-up period was reported at around 20% in prediabetic patients with sirolimus- or paclitaxel-eluting stents.[@B7] In addition, there are no data on prediabetic patients undergoing PCI according to recent guidelines on prediabetes, HbA1c of 5.7% to 6.4%,[@B8] with both 1st and 2nd generation DESs. The clinical impact and management of prediabetic patients undergoing PCI remain unknown. Therefore, we investigated the long-term clinical outcomes in prediabetic patients undergoing PCI with DES compared to normoglycemic patients.

MATERIALS AND METHODS
=====================

Study design
------------

From April 2007 to November 2010, all patients who underwent elective PCI with DESs had baseline laboratory studies, including HbA1c levels, completed before the procedure. PCI was performed using standard techniques, including predilation and subsequent intracoronary stenting. All patients were treated with aspirin and received 300-600 mg of clopidogrel preloaded before PCI, followed by daily administration of 75 mg that encouraged to be continued for at least 1 year. Other adjunctive pharmacotherapy was administered at the discretion of the operator. Repeat coronary angiography was performed for recurrent symptoms or objective evidence of ischemia during provocative testing. Routine angiographic follow up was not undertaken. Patients who did not undergo HbA1c tests were excluded, as well as patients who were already diagnosed with DM and treated with diet therapy, anti-diabetic drugs, or insulin therapy. Finally, 674 patients with an HbA1c level of \<6.5% were included in this analysis.

Approximately 24 months after the index intervention, all patients meeting criteria for this study were contacted and invited to participate in the study. After informed consent was obtained from the patient or a family member, clinical follow up performed during an outpatient visit, telephone interviews, and hospital records were reviewed. The Medical Device Institutional Review Board (IRB) of Korea University Guro Hospital approved the study protocol (IRB Number: MD09002).

Study end points
----------------

The primary end point of this study was the incidence of MACE, defined as the composite of cardiovascular mortality, myocardial infarction (MI), or need for target vessel revascularization (TVR) within 24 months of the index PCI. Secondary end points included each component of the primary end point in addition to post-procedural rehospitalization, recurrent angina, and stroke. All end point data were adjudicated by an experienced cardiovascular physician blinded to clinical details and outcomes.

Study definitions
-----------------

DM was defined as treatment with insulin or oral hypoglycemic medications or a HbA1c level ≥6.5% in non-diabetic patients. Prediabetes was defined as HbA1c of 5.7% to 6.4%. This cutoff value has been deemed to be reasonable for identifying individuals at high risk for future diabetes and to whom the term pre-diabetes may be applied.[@B8] Renal insufficiency was defined as a pre-procedural creatinine level ≥1.5 mg/dL. Procedural success was defined as \<50% residual diameter stenosis and Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow in the absence of major in-hospital complications (death, reinfarction, or urgent coronary artery bypass surgery). Acute myocardial infarction (AMI) was defined as the presence of new Q waves on a follow-up electrocardiogram or an elevation of creatinine kinase to ≥3 times normal. Cardiovascular mortality was classified as death attributable to MI, congestive heart failure, or arrhythmia.

Statistical analysis
--------------------

The SPSS 20.0 (IBM Corp., Armonk, NY, USA) statistics program was used for all analyses. For discrete variables, differences between the two groups are expressed as counts and percentages, and were analyzed with Χ^2^ or Fisher\'s exact test. For continuous variables, differences between the two groups were evaluated by unpaired t test or Mann-Whitney rank test. Data are expressed as mean±SD. Statistical significance was defined as a *p* value of 0.05. The Cox proportional hazards regression model was used to estimate the independent association between glucose levels and long-term mortality rates.

RESULTS
=======

The baseline clinical characteristics of the patients with prediabetes (group I) and the patients with normoglycemia (group II) are presented in [Table 1](#T1){ref-type="table"}. There was no significant difference in baseline characteristics between the two groups, except hypertension and prior PCI history which were higher in the prediabetic patients. Compared with normoglycemic patients, prediabetic patients tended to be older and to more commonly report prior percutaneous revascularization. As seen in [Table 2](#T2){ref-type="table"}, mean glucose levels were 104.8±51.27 mg/dL for patients with normoglycemia and 131.0±47.22 mg/dL for prediabetic patients (*p*\<0.001). While patients with prediabetes showed higher total cholesterol level, low density lipoprotein-cholesterol did not differ with that in normoglycemia patients. The characteristics of coronary angiography are presented in [Table 3](#T3){ref-type="table"}. The reference vessel diameters (2.92±0.47 mm vs. 2.98±0.51 mm,*p*=0.123) and minimal luminal diameter (0.65±0.39 mm vs.0.68±0.41 mm, *p*=0.397) of the coronary artery were similar between the two groups. No significant differences were observed between the two groups with respect to other coronary angio-graphic parameters, except diffuse long lesion was more frequent in prediabetic patients than in normoglycemic patients (39.6% vs. 31.0%, *p*=0.024). Among the procedural characteristics, there were no significant differences in stent type and number and angiographic success rate between the two groups.

Six to 9-month angiographic outcomes and major clinical outcome at 2 years are displayed in [Tables 4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. In prediabetic patients, we noted trends toward a higher incidence of binary restenosis (15.6% vs. 9.8%, *p*=0.066) and late loss (0.71±0.70 mm vs. 0.59±0.62 mm, *p*=0.076). During the 24 months of follow up, mortality rate was significantly higher in the prediabetes group than the normoglycemia group (5.5% vs.1.5%, *p*=0.007). However, the incidences of cardiac death, MI, target lesion revascularization, and TVR were similar between the two groups. In analysis of independent predictors for mortality, prediabetes, age, chronic kidney disease (CKD), and chronic total occlusion (CTO) were identified as independent predictors of 24-month mortality ([Table 6](#T6){ref-type="table"}).

DISCUSSION
==========

The present study determined that the presence of prediabetes in patients undergoing elective PCI with DESs is associated with worse mid-term angiographic outcomes and 2-year major clinical outcomes than those in patients with normoglycemia.

All stages of glucose abnormalities are associated with an increased risk of cardiovascular morbidity and mortality, making it important to identify them as early as possible.[@B9] A significant proportion of dysglycemic individuals develop vascular damage during the pre-diabetes stage, although their glucometabolic perturbations often remain undetected until the first cardiovascular event.[@B9] Prediabetes is associated with more advanced coronary artery disease, such as small vessel and diffuse coronary stenosis, compared with normoglycemia.[@B10] The prevalence of patients with prediabetes and coronary artery disease varies from study to study. A previous study reported a high prevalence of abnormal glucose tolerance in 181 patients with AMI: IGT as prediabetes comprised 35% and diabetes 31%.[@B11] In other studies, the prevalence of prediabetes and diabetes, respectively, were about 25% and 53% in patients who underwent coronary angiography.[@B10][@B12] Considering outcomes after PCI, Kataoka, et al.[@B7] reported rates of MACE and repeat revascularization of 21% and 19% in a sirolimus-eluting stent group and 23% and 22% in a paclitaxel-eluting stent group, respectively, and the overall rate of non-fatal MI was about 5%. However, these results only reflected patients with 1st generation DES. There are no data on clinical and angiographic outcomes for second generation DES in prediabetes patients. Although it is hard to compare our results with above-mentioned study directly, our results, reflecting 1st and 2nd generation DESs, showed better results, compared to previous studies, demonstrating improved current clinical situations.

Some of the discrepancy with former studies might be explained as follows: First, HbA1c cutoff values differed among studies. Cut-off values for non-diabetics in previous studies largely comprised \<6%, 6.7%, \>7%, or fourth quartile. However, patients with HbA1c ≥6.5% were excluded in our study for more exact assessment of a prediabetic state. Applying an HbA1c cut-off value ≥6.5%, as suggested by the American Diabetes Association, in previous studies, non-diabetic patients were changed as DM on admission. More recent, stricter applications of guidelines might have affected the differences in clinical outcomes. Second, most previous studies demonstrated an association between HbA1c and MACE after AMI. Our results demonstrated clinical and angiographic outcomes for patients who underwent elective PCI, exhibiting a stable disease state. Finally, we included patients with 2nd generation DESs in reflection of current clinical practice. Indeed, the everolimus-eluting stent has been shown to be associated with significantly lower rates of adverse events, compared with first generation sirolimus-eluting stents, in all-comer DM patients.[@B13]

Our study revealed trends toward higher incidences of binary restenosis and late loss at 6.9-month angiographic follow up in comparison with normoglycemic patients. This result is consistent with studies in patients with diabetes. This trend of higher restenosis might have translated into higher incidences of TVR-MACE and total MACEs.

HbA1c values reflect a 2 to 3month average endogenous exposure to glucose, including postprandial spikes in blood glucose levels, and have low intra-individual variability, particularly in persons without diabetes.[@B14] HbA1c values exceeding 6.0% may be a clinically useful marker to identify persons at risk for the development of not only diabetes but also cardiovascular disease and death.[@B15] In studies using HbA1ccorresponding to prediabetes, an abnormal HbA1c level was deemed a significant independent predictor of MACE, TVR, and cardiovascular mortality at 12 months after PCI in non-diabetic patients.[@B5][@B6][@B16][@B17] Data from the Framingham study have indicated that, even in non-diabetic patients, there is an association between HbA1c and risk of cardiovascular disease.[@B18] Kowalska, et al.[@B19] demonstrated in a cohort of non-diabetic men referred for coronary angiography that the number of diseased vessels were significantly correlated with increasing levels of HbA1c. In our study, prediabetic patients were associated with higher trends of TVR MACE and all MACE and significantly higher mortality, compared to normoglycemic patients at 24 months. Further, the presence of prediabetes, as well as older age, CKD, and CTO lesion, was an independent predictor of mortality at 24 months ([Table 6](#T6){ref-type="table"}).

Our study has several limitations. First, this was a non-randomized, single-center retrospective analysis. This might have introduced significant bias in patient and device selection. Larger, multi-center studies would reinforce our results. Second, our selection process may have limited our findings, as we did not evaluate glucose metabolic function with an OGTT, which is necessary for accurate diagnosis of IGT.[@B20] To diagnose prediabetes, our study protocol used HbA1c. No routine OGTT tests were performed to detect undiagnosed DM or prediabetes after admission, and thus, part of the observed association between hyperglycemia and outcomes might be due to undiagnosed DM or prediabetes in some patients. However, the International Expert Committee Report recommended using HbA1c assay as the preferred method for DM diagnosis, and suggested the diagnosis if HbA1c levels are ≥6.5%.[@B21] The American Diabetes Association defines prediabetes as an HbA1c of 5.7% to 6.4%.[@B8] HbA1c gives a better measure of overall glycemic exposure and likely risk for long-term complications. There is no need for fasting or timed samples, and HbA1c is less affected by conditions to produce perturbations in glucose levels. Moreover, it is a better guide for clinical management of patients. Third, in this study, routine angiographic follow-up was not performed, and thus, absolute restenosis rates of all of the study population could not be analyzed.

In conclusion, patients with prediabetes were found to be associated with higher trends of mid-term angiographic restenosis and late loss in our study. Further, there was a death rate among patients with prediabetes up to 2 years, compared to normoglycemic individuals, undergoing elective PCI with contemporary DESs. Even in the DES era, prediabetes using HbA1c can be a significant prognostic factor in patients undergoing elective PCI.
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###### Baseline Clinical Characteristics of the Study Population
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  Variables                   Group I HbA1c: 5.7--6.4% (n=242)   Group II HbA1c:\<5.7% (n=432)   *p* value
  --------------------------- ---------------------------------- ------------------------------- -----------
  Gender (male)               160 (66.1)                         289 (66.8)                      0.836
  Age (yr)                    63.44±9.96                         61.81±11.39                     0.053
  Left ventricular EF (%)     54.76±8.49                         55.14±8.33                      0.607
  BP (initial)                                                                                   
   Systolic BP (mm Hg)        120.60±16.36                       119.91±15.66                    0.574
   Diastolic BP (mm Hg)       74.47±10.14                        74.16±10.21                     0.700
  Heart rate (bpm)            71.56±8.930                        70.82±8.999                     0.313
  Unstable angina             167 (69)                           273 (63.2)                      0.639
  Prior MI                    9 (3.7)                            6 (1.3)                         0.055
  Prior PTCA                  22 (9)                             22 (5)                          0.048
  Prior CABG                  2 (0.8)                            2 (0.4)                         0.564
  Hypertension                171 (70.6)                         260 (60.1)                      0.006
  Dyslipidemia                59 (24.3)                          101 (23.3)                      0.770
  Cerebrovascular accident    16 (6.6)                           21 (4.8)                        0.344
  Peripheral artery disease   3 (1.2)                            6 (1.3)                         0.871
  Chronic kidney disease      11 (4.5)                           12 (2.7)                        0.234
  Current smoking             70 (28.9)                          116 (26.8)                      0.564

HbA1c, hemoglobin A1c; EF, ejection fraction; BP, blood pressure; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft. Data are expressed as counts (percentages) or mean±SD.

###### Laboratory Findings in the Study Population
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  Laboratory findings            Group I HbA1c:5.7--6.4% (n=242)   Group II HbA1c:\<5.7% (n=432)   *p* value
  ------------------------------ --------------------------------- ------------------------------- -----------
  HbA1c (%)                      6.25±0.139                        5.57±0.334                      \<0.001
  Glucose at admission (mg/dL)   131.0±47.22                       104.8±51.27                     \<0.001
  Total cholesterol (mg/dL)      163.7±40.96                       170.7±42.34                     0.041
  Triglycerides (mg/dL)          153.0±94.66                       138.9±93.30                     0.068
  HDL-C (mg/dL)                  43.43±10.84                       46.35±29.59                     0.151
  LDL-C (mg/dL)                  110.5±37.48                       112.0±35.45                     0.619
  LP(a) (mg/dL)                  34.47±47.80                       28.42±28.80                     0.077
  Apo-B (mg/dL)                  81.56±20.01                       77.53±21.50                     0.174
  CK-MB (max) (ng/mL)            7.24±14.01                        9.20±31.98                      0.370
  Troponin-T (max) (ng/mL)       0.066±0.26                        0.58±7.40                       0.352
  Insulin levels (IU/dL)         11.60±17.91                       9.21±19.24                      0.268
  hs-CRP (initial) (mg/L)        7.31±15.61                        7.27±17.94                      0.981
  ESR (initial) (mm/hr)          26.29±25.06                       23.47±21.29                     0.142
  Fibrinogen (mg/dL)             329.6±141.6                       307.9±123.6                     0.126
  Homocysteine (mol/L)           14.76±22.03                       12.21±5.462                     0.294

HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; LP(a), lipoprotein (a); APO-B, apolipoprotein B; CK-MB, creatine kinase-MB; hs-CRP, high sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate.

###### Coronary Angiographic Characteristics
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  Variables                          Group I HbA1c: 5.7--6.4% (n=242)   Group II HbA1c:\<5.7% (n=432)   *p* value
  ---------------------------------- ---------------------------------- ------------------------------- -----------
  Lesion site                                                                                           
   LM                                13 (5.3)                           36 (8.3)                        0.147
   LAD                               154 (63.6)                         263 (60.8)                      0.479
   LCX                               76 (31.4)                          134 (31)                        0.917
   RCA                               73 (30.1)                          136 (31.4)                      0.723
  Multivessel disease                64 (26.4)                          120 (27.7)                      0.709
  Ostial lesion (\<5 mm)             57 (23.5)                          122 (28.2)                      0.184
  Bifurcation lesion                 106 (43.8)                         196 (45.3)                      0.694
  Calcification lesion               38 (15.7)                          66 (15.2)                       0.884
  Chronic total occlusion lesion     23 (9.5)                           39 (9.0)                        0.838
  Diffuse long lesion (\>30 mm)      96 (39.6)                          134 (31.0)                      0.024
  Small vessel disease (\<2.75 mm)   116 (47.9)                         179 (41.4)                      0.103
  Total lesion length (mm)           40.19±30.49                        36.94±29.29                     0.174
  Vessel size (pre PCI, mm)          2.92±0.47                          2.98±0.51                       0.123
  Vessel size (post PCI, mm)         3.19±0.49                          3.22±0.49                       0.405
  MLD (pre PCI, mm)                  0.65±0.39                          0.68±0.41                       0.397
  MLD (post PCI, mm)                 2.91±0.48                          2.92±0.50                       0.945
  Acute gain (mm)                    2.23±0.58                          2.18±0.59                       0.414
  Number of vessel                   1.30±0.52                          1.32±0.55                       0.575
  Number of stent                    1.64±0.93                          1.58±0.91                       0.356
  Stents used                                                                                           
   Sirolimus eluting stent           95 (39.2)                          148 (34.2)                      0.196
   Paclitaxel eluting stent          71 (29.3)                          138 (31.9)                      0.482
   Zoltarolimus eluting stent        51 (21)                            93 (21.5)                       0.890
   Everolimus eluting stent          24 (9.9)                           45 (10.4)                       0.837

HbA1c, hemoglobin A1c; BP, blood pressure; LM, left main; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; PCI, percutaneous coronary intervention; MLD, minimal luminal diameter.

Data are expressed as counts (percentages) or mean±SD.

###### Angiographic Outcomes at 6 to 9 Months
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  Variables                   Group I HbA1c: 5.7--6.4% (n=166)   Group II HbA1c:\<5.7% (n=305)   *p* value
  --------------------------- ---------------------------------- ------------------------------- -----------
  Binary restenosis (\>50%)   26 (15.6)                          30 (9.8)                        0.066
  Diameter stenosis (%)       27.15±23.47                        23.65±20.10                     0.127
  MLD (mm)                    2.24±0.88                          2.39±0.82                       0.084
  Late loss (mm)              0.71±0.70                          0.60±0.62                       0.076

HbA1c, hemoglobin A1c; MLD, minimal luminal diameter.

###### Major Clinical Outcomes at 2 Years
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  Variables                         Group I HbA1c:5.7--6.4% (n=218)   Group II HbA1c:\<5.7% (n=389)   *p* value   *p* value (adjusted)   Odds ratio (95% CI)
  --------------------------------- --------------------------------- ------------------------------- ----------- ---------------------- ---------------------
  Total death, n (%)                12 (5.5)                          6 (1.5)                         0.007       0.007                  5.30 (1.52--18.4)
   Cardiac death                    4 (1.8)                           2 (0.5)                         0.125       0.124                  4.32 (0.66--27.9)
   Non-cardiac death                8 (3.6)                           4 (1)                           0.029       0.013                  14.7 (1.75--123.0)
  Any MI, n (%)                     1 (0.4)                           3 (0.7)                         0.639       0.867                  0.81 (0.07--8.88)
   Q wave                           0 (0)                             2 (0.5)                         0.182       0.993                  1.90 (--)
   Non-Q wave                       1 (0.4)                           1 (0.2)                         0.684       0.478                  4.12 (0.08--206)
  Repeat revascularization, n (%)   23 (10.5)                         35 (8.9)                        0.535       0.322                  1.33 (0.75--2.37)
   TLR                              12 (5.5)                          18 (4.6)                        0.635       0.352                  1.45 (0.66--3.20)
   TVR                              13 (5.9)                          22 (5.6)                        0.876       0.583                  1.23 (0.58--2.58)
   Non-TLR TVR                      2 (0.9)                           4 (1)                           0.894       0.968                  0.96 (0.16--5.56)
   Non TVR                          9 (4.1)                           12 (3)                          0.505       0.326                  1.58 (0.63--4.00)
  All MACE, n (%)                   33 (15.1)                         40 (10.2)                       0.082       0.069                  1.61 (0.96--2.72)
   TLR MACE                         15 (6.8)                          20 (5.1)                        0.383       0.251                  1.52 (0.74--3.14)
   TVR MACE                         24 (11)                           28 (7.1)                        0.113       0.085                  1.72 (0.92--3.21)

HbA1c, hemoglobin A1c; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization; MACE, major adverse cardiac event; CI, confidence interval.

###### Predictors of Mortality at 24 Months
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  Variables                 Hazard ratio   95% CI         *p* value
  ------------------------- -------------- -------------- -----------
  Prediabetes               5.306          1.527--18.43   0.009
  Gender (male)             0.317          0.080--1.255   0.102
  Age                       1.140          1.060--1.225   0.001
  Hypertension              4.958          0.611--40.18   0.134
  Hyperlipidemia            0.757          0.211--2.709   0.669
  Chronic kidney disease    14.668         3.101--69.36   0.001
  Current smoker            0.484          0.084--2.755   0.413
  Current alcoholic         4.470          0.711--28.09   0.110
  Multivessel disease       0.354          0.073--1.698   0.194
  Chronic total occlusion   4.743          1.007--22.33   0.049
  Bifurcation Lesion        1.569          0.520--4.727   0.424

CI, confidence interval.
